Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$4.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is crucial as it reflects the company's profitability and is a key indicator of financial health.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to scale its operations and attract investment.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as the global population ages and the demand for effective treatments rises.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly better than the expected -$0.73. However, the stock fell 3.43% the following day, indicating market disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts currently lack specific estimates for Denali's upcoming earnings, leading to uncertainty in market expectations.

Bull Case

If Denali can demonstrate significant progress in its drug development pipeline, it could attract positive attention and investment, driving the stock higher.

Bear Case

Conversely, if the earnings report reveals continued losses or setbacks in drug development, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in Denali's pipeline?

Any delays or advancements could significantly impact investor sentiment and stock performance.

How does management plan to address ongoing losses?

Investors will be closely watching for strategies to improve financial performance and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for a turnaround, particularly if there are positive updates on drug development.

Supporting Evidence

Options pricing suggests a significant move, indicating traders expect volatility that may not align with current sentiment.

The company's history of beating EPS estimates could indicate that current expectations are set too low.

Key Risk

If Denali shows unexpected progress in its drug pipeline, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around Denali's ability to turn its promising drug pipeline into a profitable business.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses could confirm the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests the stock could rise around 4.52% on the first day, confirming positive sentiment.

In-Line / Cautious

A cautious but in-line report could lead to muted reactions as investors await further clarity from management.

Miss

If the company misses expectations, history indicates a potential drop of around 2.88%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key drug candidates in the pipeline.
2Management's strategy for reducing operational losses.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for Denali's therapies.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is crucial as it reflects the company's profitability and is a key indicator of financial health.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to scale its operations and attract investment.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly better than the expected -$0.73. However, the stock fell 3.43% the following day, indicating market disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts currently lack specific estimates for Denali's upcoming earnings, leading to uncertainty in market expectations.

Bull Case

If Denali can demonstrate significant progress in its drug development pipeline, it could attract positive attention and investment, driving the stock higher.

Bear Case

Conversely, if the earnings report reveals continued losses or setbacks in drug development, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in Denali's pipeline?

Any delays or advancements could significantly impact investor sentiment and stock performance.

How does management plan to address ongoing losses?

Investors will be closely watching for strategies to improve financial performance and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for a turnaround, particularly if there are positive updates on drug development.

Supporting Evidence

Options pricing suggests a significant move, indicating traders expect volatility that may not align with current sentiment.

The company's history of beating EPS estimates could indicate that current expectations are set too low.

Key Risk

If Denali shows unexpected progress in its drug pipeline, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around Denali's ability to turn its promising drug pipeline into a profitable business.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses could confirm the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests the stock could rise around 4.52% on the first day, confirming positive sentiment.

In-Line / Cautious

A cautious but in-line report could lead to muted reactions as investors await further clarity from management.

Miss

If the company misses expectations, history indicates a potential drop of around 2.88%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key drug candidates in the pipeline.
2Management's strategy for reducing operational losses.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for Denali's therapies.
5Future guidance on revenue expectations.